Head-to-head comparison
LillyDirect Foundayo vs NowPatient
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.
Marked down on: Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
Desk Score
NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.
$1,349/mo (brand-name) sema · $1,069/mo (brand-name) tirz · Verified July 2026
Marked down on: Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
LillyDirect Foundayo takes this head-to-head with the higher Desk Score, 82/100 (B−) against 59/100 (C) for NowPatient. NowPatient still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
LillyDirect Foundayo
82/100
B−
NowPatient
59/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | LillyDirect Foundayo | NowPatient |
|---|---|---|
| Semaglutide | Not listed on LillyDirect Foundayo's site (checked July 2026) | $1,349/mobrand-name$1,349/mo (brand Wegovy) |
| Tirzepatide | Not listed on LillyDirect Foundayo's site (checked July 2026) | $1,069/mobrand-name$1,069/mo (brand Mounjaro, promotional rate) |
| Coverage | All 50 states | Not listed on NowPatient's site (checked July 2026) |
| Brand-name | Yes | Yes |
| Oral option | Yes | Yes |
| Best for | Patients with commercial insurance who want the cheapest legal brand-name GLP-1. | Brand-name GLP-1 access without a compounded route. |
| Desk Score | 82/100B− | 59/100C |
The verdict
Desk pick — LillyDirect FoundayoLillyDirect Foundayo takes this head-to-head with the higher Desk Score, 82/100 (B−) against 59/100 (C) for NowPatient. NowPatient still holds its ground where its strengths line up with yours.
Choose LillyDirect Foundayo if…
Patients with commercial insurance who want the cheapest legal brand-name GLP-1.
All 50 states
Choose NowPatient if…
Brand-name GLP-1 access without a compounded route.
$1,349/mo (brand-name) sema · $1,069/mo (brand-name) tirz
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: LillyDirect Foundayo · NowPatient.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs LillyDirect Foundayo
- CoreAge Rx vs NowPatient
- LillyDirect Foundayo vs Sesame Care
- Gala Health vs NowPatient
- LillyDirect Foundayo vs RxSpan MD
- Levity vs NowPatient
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.